Hansa Biopharma Ab Stock Book Value Per Share
| HNSA Stock | SEK 30.68 0.80 2.68% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Stock. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma stock.
Hansa |
Hansa Biopharma AB Company Book Value Per Share Analysis
Hansa Biopharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Hansa Biopharma Book Value Per Share | 11.55 X |
Most of Hansa Biopharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Hansa Biopharma AB is about 11.553 times. This is 779.59% lower than that of the Healthcare sector and 104.65% lower than that of the Biotechnology industry. The book value per share for all Sweden stocks is 99.4% higher than that of the company.
Hansa Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in book value per share category among its peers.
Hansa Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.80) % | |||
| Current Valuation | 2.17 B | |||
| Shares Outstanding | 52.44 M | |||
| Shares Owned By Insiders | 7.37 % | |||
| Shares Owned By Institutions | 41.33 % | |||
| Price To Book | 7.52 X | |||
| Price To Sales | 17.67 X | |||
| Revenue | 154.53 M | |||
| Gross Profit | 116.05 M | |||
| EBITDA | (585.52 M) | |||
| Net Income | (609.57 M) | |||
| Cash And Equivalents | 762.73 M | |||
| Cash Per Share | 19.06 X | |||
| Total Debt | 783.93 M | |||
| Debt To Equity | 1.60 % | |||
| Current Ratio | 15.45 X | |||
| Book Value Per Share | 11.55 X | |||
| Cash Flow From Operations | (504.36 M) | |||
| Earnings Per Share | (13.10) X | |||
| Target Price | 171.0 | |||
| Number Of Employees | 150 | |||
| Beta | 0.88 | |||
| Market Capitalization | 2.82 B | |||
| Total Asset | 1.69 B | |||
| Z Score | 1.8 | |||
| Net Asset | 1.69 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.